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Abstract
Background: Illicit drug overdose remains a leading cause of premature mortality in urban settings worldwide. We sought
to estimate the number of deaths potentially averted by the implementation of a medically supervised safer injection facility
(SIF) in Vancouver, Canada.
Methodology/Principal Findings: The number of potentially averted deaths was calculated using an estimate of the local
ratio of non-fatal to fatal overdoses. Inputs were derived from counts of overdose deaths by the British Columbia Vital
Statistics Agency and non-fatal overdose rates from published estimates. Potentially-fatal overdoses were defined as events
within the SIF that required the provision of naloxone, a 911 call or an ambulance. Point estimates and 95% Confidence
Intervals (95% CI) were calculated using a Monte Carlo simulation. Between March 1, 2004 and July 1, 2008 there were 1004
overdose events in the SIF of which 453 events matched our definition of potentially fatal. In 2004, 2005 and 2006 there
were 32, 37 and 38 drug-induced deaths in the SIF’s neighbourhood. Owing to the wide range of non-fatal overdose rates
reported in the literature (between 5% and 30% per year) we performed sensitivity analyses using non-fatal overdose rates
of 50, 200 and 300 per 1,000 person years. Using these model inputs, the number of averted deaths were, respectively: 50.9
(95% CI: 23.6–78.1); 12.6 (95% CI: 9.6–15.7); 8.4 (95% CI: 6.5–10.4) during the study period, equal to 1.9 to 11.7 averted
deaths per annum.
Conclusions/Significance: Based on a conservative estimate of the local ratio of non-fatal to fatal overdoses, the potentially
fatal overdoses in the SIF during the study period could have resulted in between 8 and 51 deaths had they occurred
outside the facility, or from 6% to 37% of the total overdose mortality burden in the neighborhood during the study period.
These data should inform the ongoing debates over the future of the pilot project.
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Introduction
Illicit drug overdose remains a leading cause of death and
disability inmanyurban settingsworldwide [1–3].Forinjection drug
users (IDU), the annual rate of fatal overdose is estimated to between
one and three per cent per year and is the primary contributor to
mortality rates many times higher than in non-IDU populations [4–
7]. Thus,interventionsto reduce mortality from overdose arecentral
to efforts to reduce the harms of illicit drug use.
In Vancouver, Canada, the number of fatal overdoses reached
unprecedented levels at the end of the 1990s, especially in the
Downtown Eastside (DTES) neighbourhood, the site of an open
drug market and explosive outbreaks of HIV and hepatitis (HCV)
[8]. In response, North America’s first medically supervised safer
injecting facility (SIF), named Insite, opened in the DTES in
March, 2003. The pilot facility has been the subject of a
comprehensive evaluation [9,10]. Among its findings are a
significant increase in uptake to drug and alcohol treatment
[11]; a decrease in local measures of drug-related disorder,
including public injecting [12]; and a reduction in the prevalence
of risk factors for HIV infection, such as syringe sharing [13].
In addition to these public health objectives, the facility aims to
reduce the risk of death for clients by providing prompt and
appropriate medical attention in the event of an on-site overdose
[9]. We have previously reported that the annual incidence of non-
fatal overdose in a representative sample of SIF users was
approximately 20 per 1,000 person years [14]; and that while
on-site non-fatal overdoses were common during the first
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resulted in a fatality [15]. Despite the international evidence
suggesting a beneficial effect of SIF on overdose mortality [16–18],
we are unaware of any peer-reviewed studies that quantify the
number of deaths prevented by such a facility. These estimates are
obviously important for cost-effectiveness studies and other
indicators. Thus, we sought to estimate the number of overdose
fatalities averted in Vancouver’s SIF.
Results
From the initiation of the SIF database on March 1, 2004 until
February 6, 2008, there were 766,486 injections in the facility,
resulting in 1004 overdose events (1.31 per 1,000 injections, or 0.63
per day) in the facility. None resulted in death. The physical
manifestations, the substances consumed and the responses taken by
staff to these overdose events are shown in Table 1. Of the 1004
overdose events, 453 (45.1% or 0.28 per day) required the provision
of naloxone, a 911 call and/or an ambulance, and were included as
potential fatal overdoses in our analysis. In approximately 68% of
on-site overdose events during the study period, the primary
substance injected was heroin, followed by cocaine (17%).
From 2004 to 2006, the British Columbia Vital Statistics
Agency reported 32, 37 and 38 annual drug-induced deaths in the
Downtown Eastside. The median number of drug-induced deaths
per annum from 1998 to 2006 was 38.3. The model inputs for the
number of fatal overdoses for each year of the study period, as well
as all other model inputs, are reported in Table 2.
Model results, including the DTES fatal overdose rate, the
estimated ratio of fatal to non-fatal overdoses in the DTES, the
estimated number of non-fatal overdoses in the DTES, and the
estimated number of on-site deaths averted, expressed as both a
count and a proportion of DTES overdose deaths, are presented in
Table 3. The fatal overdose rate in the DTES over the study
period was 5.6 per 1,000 person years. Over the same period, the
estimated ratio of non-fatal to fatal overdose ranged from 8.9:1
(given a non-fatal overdose ratio of 50 per 1,000 person years) to
53.8:1 (given 300 per 1,000 person years).
Using these inputs, the number of overdose deaths averted in
the SIF over the study period was 50.9 (95% CI: 23.6–78.1); 12.6
(9.6–15.7); 8.4 (6.5–10.4) given different estimated rates of non-
fatal overdose. The number of averted deaths is equal to between
two and 12 per annum over the study period.
Discussion
Using data from North America’s first SIF and published
estimates of the rate of non-fatal overdose among active IDU, we
derived an estimate of the number of fatal overdoses averted by a
supervised injecting facility. Following a Monte Carlo simulation
and a three-part sensitivity analysis, the estimates of the number of
prevented deaths ranged from eight to 51 from March 1, 2004 to
July 1, 2008.
The estimate of the number of deaths prevented is equal to a
substantial proportion of the total burden of overdose mortality in
the area during the study period. Despite the pilot facility only
hosting, by design, approximately five per cent of the daily
injections in the DTES, the estimated number of averted deaths
was equal to between 6.1 and 37.0 per cent of the total overdose
burden in the area during the study period. It is impossible to
declare with certainty if the SIF prevented these fatalities as it is
not possible to know if overdoses occurring in the SIF would have
occurred elsewhere. However, despite charges to the contrary
[19], a longitudinal analysis of overdose patterns in a represen-
tative sample of SIF clients did not demonstrate that individuals
took greater risks—i.e., in drug choice, mode of administration or
dose—within the apparent safety of an SIF [14].
Our results are similar to those in an evaluation of the medically
supervised injection centre (MSIC) in Sydney, Australia [16].
Using a similar method, they estimated that six of the 81 non-fatal
overdoses in the MSIC that required naloxone during its first
18 months of operation would have resulted in a fatality, or
between four and nine deaths prevented per annum, given
different methodological assumptions. This rate is within the range
of two to 12 per annum estimated by our methodology.
Our results differ from those in an unpublished cost-effectiveness
report prepared for Canada’s federal health minister [20] that
estimated Insite prevented 1.08 deaths per year, an estimate below
the range of the per annum calculation of our model. However, it
should be noted that the report’s figure was the result of an
extrapolation of published and aggregated data from the first
18 months of operation; the authors were unable to benefitfrom SIF
data fromthe first four yearsof operation;nordid theirmethodology
account for the uncertainty surrounding several parameters. We
believe the authors’ population-level estimates of overdose risk
differed due to the above issues as well as failure to account for the
higher risk drug-using patterns of the SIF clientele [10,21].
Obviously, the optimal strategy to evaluate the impact of the
SIF on overdose rates would be to randomize participants to use
(versus restricted use) of the SIF. This approach has been deemed
unethical [9]. In the absence of a randomized trial, there are
several approaches to assess possible effects on fatal overdose
including modelling, as we have employed, and crude time series
analyses comparing year-to-year changes in mortality rates. With
respect to time-series approaches, previous work has identified
how overdose rates are influenced by a diverse array of factors
which change over time, such as drug purity. We have recently
shown large fluctuations in local drug purity[22]. Other factors
affecting overdose risk include age [23], drug choice [24],
exposure to addiction treatment [25] and incarceration history
[26]. While little work has been done on the population-level
determinants of overdose mortality rates, it is reasonable to assume
analogous factors are at work, including drug market dynamics,
law enforcement patterns and the coverage of harm reduction
measures. Because of this multiplicity of effects and the potential
for unmeasured confounding due to drug supply changes in crude
time series analyses, we are unaware of any method using available
data that could identify the impact of the SIF on population-level
overdose rates. Thus, we chose to estimate the number of averted
overdose deaths using published estimates and observed, individ-
ual-level data from the SIF.
These findings have immediate policy implications. First, despite
initially expressing interest in analyses of Insite’s impact on local
patterns of overdose [27], Canada’s federal government more
recently announced its opposition to the continued operation of the
facility and appealed a local court ruling blocking its closure [28].
Regardless of these partisan political developments, this analysis
provides evidence of the likely beneficial effect of the facility on the
risk of overdose death in the DTES and echoes previous findings
from Sydney’s MSIC [16]. Together, these findings support the
increasingly prevalent conclusion that supervised injection facilities
are an effective and appropriate intervention in urban settings
suffering from high levels of overdose deaths.
Our analysis has several limitations, chiefly the reliance on
estimates to inform several model parameters, specifically the
number of IDU in the DTES and the incidence of non-fatal
overdose in the community. For the former, we relied on two
previous capture-recapture studies [29,30] and included a wide
confidence interval in the Monte Carlo simulation. For the latter,
OD Deaths Averted in SIF
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non-fatal overdose rates reported in the literature. Model outputs
such as the DTES fatal overdose rate and non-fatal to fatal overdose
ratio are not substantially different from previous observations in
other settings [31], lending credence to the estimate of averted
deaths. Furthermore, in every case, we endeavoured to use
conservative estimates, for example restricting the definition of a
potential on-site overdose death to those characterised by a 911 call,
provision of naloxone and/or an ambulance. Finally, there may be
effects of the SIF that go beyond their impact on those actively using
Table 1. SIF overdose events by year, substances used, characteristics and interventions
2004
= 2005 2006 2007 2008
W ALL
OD events 189 246 230 201 138 1004
ODs/day 0.62 0.68 0.63 0.55 0.76 0.63
Injections 136,971 178,787 178,847 183,989 87,892 766,486
ODs/injection
{ 1.38 1.38 1.29 1.09 1.57 1.31
OVERDOSE: SUBSTANCES USED
n (%) n (%) n (%) n (%) n (%) n (%)
Cocaine 39 (20.6) 48 (19.5) 44 (19.1) 24 (11.9) 14 (10.1) 169 (16.8)
Crack cocaine 4 (2.1) 1 (0.4) 1 (0.4) 5 (2.5) 2 (1.4) 13 (1.3)
Dilaudid 5 (2.6) 5 (2.0) 4 (1.7) 2 (1.0) 3 (2.2) 19 (1.9)
Heroin 132 (69.8) 164 (66.7) 140 (60.9) 144 (71.6) 103 (74.6) 683 (68.0)
Methadone 2 (1.1) 1 (0.4) 1 (0.4) 4 (2.0) 0 (0.0) 8 (0.8)
Crystal meth 1 (0.5) 0 (0.0) 2 (0.9) 5 (2.5) 1 (0.7) 9 (0.9)
Morphine 3 (1.6) 5 (2.0) 3 (1.3) 8 (4.0) 2 (1.4) 21 (2.1)
Speedball 11 (5.8) 30 (12.2) 22 (9.6) 15 (7.5) 10 (7.2) 88 (8.8)
Talwin & Ritalin 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
OVERDOSE: CHARACTERISTICS
n (%) n (%) n (%) n (%) n (%) n (%)
Unable to speak 9 (4.8) 44 (17.9) 48 (20.9) 60 (29.9) 51 (37.0) 212 (21.1)
Passed out 8 (4.2) 37 (15.0) 28 (12.2) 27 (13.4) 24 (17.4) 124 (12.4)
Limp 78 (41.3) 120 (48.8) 118 (51.3) 109 (54.2) 78 (56.5) 503 (53.1)
Face blue/pale 71 (37.6) 123 (50.0) 120 (52.2) 119 (59.2) 45 (32.6) 478 (47.6)
Breath slow 106 (56.1) 145 (58.9) 125 (54.3) 117 (58.2) 72 (52.2) 565 (56.3)
Breath stopped 24 (12.7) 52 (21.1) 38 (16.5) 51 (25.4) 23 (16.7) 188 (18.7)
Chest tightness 4 (2.1) 6 (2.4) 3 (1.3) 6 (3.0) 1 (0.7) 20 (2.0)
Seizure 18 (9.5) 15 (6.1) 45 (19.6) 30 (14.9) 8 (5.8) 116 (11.6)
Vomiting 1 (0.5) 1 (0.4) 3 (1.3) 5 (2.5) 2 (1.4) 12 (1.2)
Choking 1 (0.5) 5 (2.0) 3 (1.3) 3 (1.5) 3 (2.2) 15 (1.5)
Sweaty/hot skin 16 (8.5) 31 (12.6) 24 (10.4) 42 (20.9) 28 (20.3) 141 (14.0)
Cold skin 33 (17.5) 37 (15.0) 43 (18.7) 43 (21.4) 28 (20.3) 184 (18.3)
Other 24 (12.7) 12 (4.9) 21 (9.1) 24 (11.9) 13 (9.4) 94 (9.4)
No response to verbal
stimulus
22 (11.6) 83 (33.7) 84 (36.5) 71 (35.3) 61 (44.2) 321 (32.0)
No response to pain
stimulus
33 (17.5) 110 (44.7) 87 (37.8) 69 (34.3) 58 (42.0) 357 (35.6)
OVERDOSE: RESPONSES
n (%) n (%) n (%) n (%) n (%) n (%)
911 call 54 (28.6) 123 (50.0) 95 (41.3) 93 (46.3) 58 (42.0) 423 (42.1)
CPR 1 (0.5) 4 (1.6) 1 (0.4) 0 (0.0) 0 (0.0) 6 (0.6)
Oxygen 152 (80.4) 202 (82.1) 188 (81.7) 176 (87.6) 92 (66.7) 810 (80.7)
Artificial respiration 18 (9.5) 54 (22.0) 45 (19.6) 45 (22.4) 19 (13.8) 181 (18.0)
Ambulance 14 (7.4) 27 (11.0) 32 (13.9) 33 (16.4) 22 (15.9) 128 (12.7)
Naloxone 0.4 mg 35 (18.5) 89 (36.2) 59 (25.7) 56 (27.9) 46 (33.3) 285 (28.4)
Naloxone 0.4 mg62 23 (12.2) 44 (17.9) 25 (10.9) 25 (12.4) 24 (17.4) 141 (14.0)
Airway inserted 7 (3.7) 50 (20.3) 50 (21.7) 46 (22.9) 26 (18.8) 179 (17.8)
=March 1, 2004 to December 31, 2004/
WJanuary 1, 2008 to July 1, 2008/
{OD events per 1,000 injections
doi:10.1371/journal.pone.0003351.t001
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education in safer injection practices which may reduce risk
behaviours for overdose outside the facility. Over one-third of
individuals report receiving this training in a representative cohort of
SIF clients [32]. Although this issue requires further study, IDU who
experience supervision of a nurse within the SIF may subsequently
be more cautious when injecting in environments which are not
supervised by trained emergency personnel [33].
In conclusion, we observed that non-fatal overdose was a
common occurrence at Vancouver’s SIF and, using a modelling
technique based on evidence-based parameter values, we estimat-
ed that the facility prevented between eight and 51deaths over the
study period. This is equal to between 37.0 per cent and 6.1 per
cent of overdose fatalities in the DTES over the same time or two
to 12 averted deaths per annum over the study period. These
findings are consistent with analogous evaluations and support the
conclusion of the facility’s positive impact on public health in
Vancouver’s Downtown Eastside [10].
Materials and Methods
In this analysis, we sought to estimate the number of overdose
deaths averted by a supervised injection facility using methods
described previously [16,31,34,35]. This estimate was calculated
by determining how many overdose events in the SIF would have
been fatal had they happened outside the facility [16]. Specifically,
the number of averted deaths is the product of the number of on-
site overdoses multiplied by the ratio of fatal to non-fatal overdoses
in the DTES [31], or:
fODAVERTED~nfODSIF: fODDTES
nfODDTES

For each term in the equation, we used evidence-based estimates
Table 2. Observations and model parameters for Monte Carlo
simulation
2004
= 2005 2006 2007 2008
W ALL
OBSERVATIONS
DTES OD deaths 20.1 27.8 28.5 28.7 14.4 137.7
SIF OD events 71 126 99 95 62 453
MODEL PARAMETERS
IDU in DTES N (4700, 500)
Non-fatal OD rate Scenario 1: N (0.05, 0.01)
Scenario 2: N (0.2, 0.01)
Scenario 3: N (0.3, 0.01)
=March 1, 2004 to December 31, 2004/
WJanuary 1, 2008 to July 1, 2008
doi:10.1371/journal.pone.0003351.t002
Table 3. DTES fatal overdose rate, non-fatal to fatal overdose ratio and SIF averted deaths from model
2004
1 2005 2006 2007 2008
2 ALL
DTES fatal OD
rate
3
5.1 (4.0–6.2) 5.9 (4.6–7.2) 6.1 (4.7–7.4) 5.3 (4.1–6.4) 5.3 (4.1–6.4) 5.6 (4.3–6.8)
NON-FATAL TO FATAL OVERDOSE RATIO
Scenario 1
4 9.7 (5.4–14.0) 8.4 (4.6–12.1) 8.2 (4.5–11.9) 9.4 (5.1–13.7) 9.4 (5.2–13.7) 8.9 (4.9–12.9)
Scenario 2
5 39.0 (30.1–47.9) 33.8 (26.0–41.6) 32.9 (25.2–40.6) 37.9 (29.1–46.7) 37.9 (29.2–46.6) 35.8 (27.6–44.1)
Scenario 3
6 58.5 (45.7–71.3) 50.8 (39.6–61.9) 49.4 (38.5–60.3) 56.9 (44.4–69.3) 56.9 (44.4–69.4) 53.8 (42.0–65.6)
NON-FATAL OVERDOSES IN DTES
Scenario 1 195.4 (108.7–282.1) 232.1 (127.8–336.5) 232.9 (127.7–338.2) 232.3 (126.4–338.1) 116.7 (63.9–169.6) 1010.7 (557.5–1463.9)
Scenario 2 784.7 (605.6–963.8) 939.0 (722.6–1155.3) 937.9 (719.1–1156.7) 937.9 (720.5–1155.3) 470.3 (362.1–578.4) 4068.3 (3129.8–5006.8)
Scenario 3 1176.4 (918.7–1434.1) 1408.8 (1099.8–1717.9) 1407 (1097.2–1717.3) 1407.3 (1099.6–1715.1) 705.8 (551.0–860.7) 6108.9 (4770.3–7447.6)
SIF AVERTED OVERDOSE DEATHS
Scenario 1 7.3 (3.4–11.3) 15.1 (1.9–28.3) 12.1 (5.6–18.7) 10.1 (4.3–15.9) 6.6 (3.0–10.2) 50.9 (23.6–78.1)
Scenario 2 1.8 (1.4–2.3) 3.7 (2.8–4.6) 3.0 (2.3–3.7) 2.5 (1.9–3.1) 1.6 (1.2–2.0) 12.6 (9.6–15.7)
Scenario 3 1.2 (0.9–1.5) 2.5 (1.9–3.1) 2 (1.5–2.5) 1.7 (1.3–2.1) 1.1 (0.8–1.3) 8.4 (6.5–10.4)
SIF AVERTED OVERDOSE DEATHS (PROPORTION OF DTES OD DEATHS)
Scenario 1 36.3 (16.9–56.2) 54.3 (6.8–101.8) 42.5 (19.6–65.6) 35.2 (15.0–55.4) 23.0 (10.4–35.5) 37.0 (17.1–56.7)
Scenario 2 9.0 (7.0–11.4) 13.3 (10.1–16.5) 10.5 (8.1–13.0) 8.7 (6.6–10.8) 5.6 (4.2–7.0) 9.2 (7.0–11.4)
Scenario 3 6.0 (4.5–7.5) 9.0 (6.8–11.2) 7.0 (5.3–8.8) 5.9 (4.5–7.3) 3.8 (2.8–4.5) 6.1 (4.7–7.6)
SIF AVERTED OVERDOSE DEATHS (PER YEAR)
Scenario 1 11.7 (5.4–18.0)
Scenario 2 2.9 (2.2–3.6)
Scenario 3 1.9 (1.5–2.4)
1March 1, 2004 to December 31, 2004
2January 1, 2008 to February 6, 2008
3Expressed as deaths per 1,000 person years
4Scenario 1: Non-fatal overdose incidence is 50 per 1,000 person years or 5% per person per year
5Scenario 2: Non-fatal overdose incidence is 200 per 1,000 person years or 20% per person per year
6Scenario 3: Non-fatal overdose incidence is 300 per 1,000 person years or 30% per person per year
doi:10.1371/journal.pone.0003351.t003
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(nfODSIF) was compiled from the facility’s comprehensive on-site
surveillance database. This system was the source of data for an
earlier analysis of SIF overdose patterns and has already been
described in detail [15]. Briefly, all new clients must register at the
SIF using a pseudonymous identifier and basic information (i.e.,
gender and age). All activities in the SIF, including the type and
amount of substances injected, the characteristics of overdose
events and the interventions taken in response, are entered into the
database and associated with the client’s identifier.
For this analysis, we accessed a dataset from the SIF with all
pseudonymous identifiers stripped. In order to limit our analysis to
on-site overdose events that might conceivably resulted in a death,
we restricted our definition of a potentially-fatal overdose event as
any that required the provision of naloxone, a 911 call and/or an
ambulance.
The ratio of fatal to non-fatal overdoses in the DTES was
estimated using data from various official or peer-reviewed sources.
The incidence of fatal overdose (fODDTES) was calculated using
counts of drug-induced deaths in the Downtown Eastside published
annually by the British Columbia Vital Statistics Agency [36-44]. As
these totals included deaths from drug overdose as well as suicide by
drug poisoning and adverse events from medications, we multiplied
the counts by 75%, the approximate proportion of deaths from drug
overdoses [44]. The number of person-years at risk was calculated
using estimates of the sizeof the IDUpopulation intheDTESintwo
recent capture-recapture studies[29,30]. The local incidenceofnon-
fatal overdose (nfODDTES) was estimated from a review of cross-
sectional and longitudinal surveys of active IDU in both domestic
and international settings [3,5,14,23,24,31,45–52]. Both rates were
expressed per 1,000 person years.
A small amount of data was missing and its value was imputed.
Counts of drug-induced deaths in the DTES were unavailable for
2007 and 2008. Thus, the median number of fatal overdoses per
annum between 1997 and 2006 was used for both 2007 and 2008.
For 2008, we multiplied this number by the proportion of the year
included in our study period.
We accounted for the uncertainty in some model parameters in
two ways. First, we performed a Monte Carlo simulation for each
year of the study period and the entire study period. By permitting
the mean, variability and distribution for each model value to be
defined, Monte Carlo simulations enable the calculation of point
estimates and 95% Confidence Intervals (95% CI) for model
outputs. For each year in the study period we performed 10,000
iterations; for the entire study period, we performed 50,000
iterations. We have previously used the Monte Carlo method to
model the impact of antiretroviral medication on mortality from
HIV infection in the DTES [35] and the Americas [34]. Second,
owing to the wide range of non-fatal overdose rates cited in the
literature, we conducted a sensitivity analysis by repeating the
Monte Carlo simulation three times, using different plausible
values for the local non-fatal overdose rate: 50 per 1,000 person
years, reflecting the lowest value observed in a local cohort of IDU
[24]; 200 per 1,000 person years, the median value observed in a
local cohort of IDU [14]; and 300 per 1,000 person years, the
largest external estimate observed [31].
In a subanalyses, we calculated estimates of the number of non-
fatal overdoses in the DTES for each year in the study period as
well as the entire study period. These estimates are the product of
the number of fatal overdoses defined in the model multiplied by
the non-fatal to fatal overdose ratio. As above, we performed
Monte Carlo simulations using three different non-fatal overdose
rates to calculate three point estimates with 95% CI.
The evaluation of Vancouver’s SIF has been reviewed and
approved by the University of British Columbia/Providence
Healthcare Research Ethics Board.
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